Stockwinners Market Radar for May 18, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT Cathie Wood's ARK Investment bought 287K shares of Palantir today

19:05 EDT Ares Management exec Berry sells 15,000 class A shares - In a regulatory filing, Ares Management chief marketing and strategy officer Ryan Berry disclosed the sale of 15,000 class A common shares of the company on May 17 at a price of $82.95 per share.

18:53 EDT Ontario Teachers Pension Plan Board sells 7M class A shares of Azek - In a regulatory filing, the Ontario Teachers Pension Plan Board disclosed the sale of 7M class A common shares of Azek on May 16 at a price of $24.36 per share.

18:34 EDT Lesaka announces buyback of 250K shares of common stock - Lesaka "announced that it has repurchased approximately 250,000 of the Company's common shares in May 2023, at a price of $3.26 per share."

18:09 EDT Ritchie Bros. CEO buys $1.0M in common stock - In a regulatory filing, Ritchie Bros. disclosed that its CEO Ann Fandozzi bought 18.5K shares of common stock on May 18th in a total transaction size of $1.0M.

17:46 EDT Qorvo CEO Bruggeworth sells 17,063 common shares - In a regulatory filing, Qorvo president and CEO Robert Bruggeworth disclosed the sale of 17,063 common shares of the company on May 17 at a price of $90.73 per share.

17:26 EDT JFrog director sells $1.0M in common stock - In a regulatory filing, JFrog disclosed that its director Frederic Simon sold 45K shares of common stock on May 17th in a total transaction size of $1.0M.

17:20 EDT Lockheed Martin awarded $750.55M Air Force contract - Lockheed Martin was awarded a $750.55M firm-fixed-price contract for Lot 21 Joint Air-to-Surface Standoff Missile B-2 missiles with containers, tooling and test equipment, and spares. Work is expected to be completed by August 18, 2027. This contract involves Foreign Military Sales, or FMS, to Australia. This award is the result of a sole source acquisition. Fiscal 2023 Air Force missiles procurement funds in the amount of $737.67M; FY23 Air Force operations and maintenance funds in the amount of $209,098; FY22 Air Force missiles procurement funds in the amount of $4.84M and FMS funds in the amount of $7.83M are being obligated at the time of award. Air Force Life Cycle Management Center is the contracting activity.

17:13 EDT Norfolk Southern and union reach agreement on paid sick leave per year - The Brotherhood of Locomotive Engineers and Trainmen BLET and Norfolk Southern Corporation announced Thursday that they have reached an agreement to provide up to seven paid sick days per year to BLET members. The agreement will provide Norfolk Southern engineers with five new days of paid sick leave per year while also offering them the flexibility to use up to two additional days of existing paid time off as sick leave. The new agreement will provide new paid sick leave benefits to over 3,300 Norfolk Southern engineers, representing almost 25% of the NS craft workforce. With this agreement, almost all of the company's craft employees - approximately 98%, have entered into paid sick leave deals."We are proud to be the first to have reached a paid sick leave agreement for our dedicated BLET membership," said Dewayne Dehart, BLET general chairman . "This trailblazing new deal ensures that engineers finally have access to the time they need and deserve to manage their personal well-being."

17:10 EDT Fastly CEO Nightingale sells 74,084 class A shares - In a regulatory filing, Fastly CEO Todd Nightingale disclosed the sale of 74,084 class A common shares of the company on May 16 at a price of $13.17 per share.

17:02 EDT Motorola Solutions Chairman Brown sells $16M in company shares - The Chairman of Motorola Solutions Gregory Brown disclosed in a regulatory filing that he had sold 53,500 shares of stock at $291.43 per share on May 16 for a total transaction amount of $15,591,334.

17:00 EDT ModivCare resolves dispute with former CEO Daniel Greenleaf - Modivcare announced that the company and its former Chief Executive Officer, Daniel E. Greenleaf, have recently resolved a disagreement regarding the nature of his departure and the amount of compensation owed to him following his departure from the Company effective August 1, 2022. Modivcare's Board Chairman, Christopher Shackelton, stated, "Modivcare appreciates the leadership Dan provided to the company during a critical time, allowing the company to navigate the challenges posed by COVID. We wish him the best on his next challenge." Mr. Greenleaf stated, "I continue to believe in Modivcare's mission, and it was an honor to work with so many others dedicated to that mission."

16:52 EDT KLA Corp's Khan sells $776K in company shares - Officer of KLA Corp, Ahmad Khan, disclosed in a regulatory filing that he had sold 1,915 shares of stock at $405.00 per share on May 16, for a total transaction amount of $775,575.

16:41 EDT D.R. Horton COO Romanowski sells $4.5M in company shares - The COO of DR Horton Paul Romanowski disclosed in a regulatory filing that he had sold 40,000 shares of stock at $112.16 per share on May 17, for a total transaction amount of $4,486,524.

16:33 EDT Kadant authorizes share repurchase of up to $50M - Kadant has authorized the repurchase of up to $50M of its equity securities effective May 18, 2023 through May 18, 2024. The company has not repurchased any shares of its common stock under the $50M authorization that will expire on May 19, 2023.

16:30 EDT Zillow Group names Jeremy Hofmann CFO - Zillow Group announced Jeremy Hofmann has been promoted to chief financial officer. He succeeds Allen Parker, who will transition to an advisory role into the first quarter of 2024. Hofmann joined Zillow Group nearly six years ago and most recently served as senior vice president of corporate development and strategy, with deep experience in strategy, finance, budgeting and operations rigor, investor relations, mergers and acquisitions and partnerships. Notably, Jeremy led Zillow's redefined Housing Super App strategy in early 2022 and has been a key driver of its execution over the past 18 months. "Jeremy has been an integral part of Zillow's growth since he joined the company," says Zillow co-founder and CEO Rich Barton. "He's at the center of our strategy to capture a greater share of customer transactions in real estate while making it easier for more and more people to get home. Jeremy is key in driving progress on our growth strategy with operational and financial discipline, and I'm looking forward to him having an even bigger hand in shaping the future of Zillow as our CFO."

16:21 EDT Noodles & Company announces resignation of CFO Carl Lukach - Noodles & Company announced the resignation of Chief Financial Officer, Carl Lukach, effective June 9. Mr. Lukach has accepted a similar role at a company in the retail industry which will allow him to be closer to family. Dave Boennighausen, Chief Executive Officer of Noodles & Company, said, "Carl has been a great asset to the Company since he joined in 2020. On behalf of the entire Noodles team, I would like to thank Carl for his leadership and dedication, and we wish him the best in his next endeavor."

16:17 EDT TechnipFMC awarded RLWI contract by Equinor - TechnipFMC (FTI) has been awarded a significant contract by Equinor (EQNR) to provide riserless light well intervention, or RLWI, services on the Norwegian Continental Shelf. The two-year contract runs from 2024 to 2025, with options to extend for each of the three subsequent years. TechnipFMC will provide production enhancement, production data, and pre-plug-and-abandonment services to Equinor using the RLWI method. RLWI enables well interventions from a monohull vessel, eliminating the need for a riser and the rig required to connect the riser to the subsea well. Instead, remotely operated Well Control Systems are used to facilitate operations on the seabed. This reduces cost and complexity, increases efficiency, and accelerates the timeframe for increased production. For TechnipFMC, a "significant" contract is between $75 million and $250 million. This award will be included in inbound orders in the second quarter of 2023. "

16:16 EDT DXC Technology names Rob Del Bene as new CFO - DXC Technology "announced that Rob Del Bene has been appointed Executive Vice President and Chief Financial Officer, reporting to DXC Chairman, President and Chief Executive Officer Mike Salvino. He will officially begin his role effective June 15, 2023, succeeding CFO Ken Sharp, who is leaving DXC for personal reasons and will remain at DXC until September 15, 2023, to help ensure a smooth transition. Del Bene is a seasoned financial executive with more than 40 years of experience in various senior leadership positions. He has served as IBM's Vice President and Controller; General Manager, IBM Global Financing; Vice-President and Treasurer; and other senior roles."

16:13 EDT QCR Holdings promotes Chief Information Officer Reba Winter to COO role - QCR Holdings announced that Chief Information Officer , Reba Winter, has been promoted to Chief Operating Officer of the Company. "We are pleased to announce that we have promoted Reba Winter to Chief Operating Officer of the Company," said Larry J. Helling, Chief Executive Officer. "In her prior role as Chief Information Officer, Reba has led our Company through several very successful projects, including the integration and conversion of our recent acquisition of Guaranty Bank. Reba has also demonstrated a deep understanding of the intersection of technology and operations and their impact on how we serve our clients. "In her new role, Ms. Winter will continue to report to Todd Gipple, President and Chief Financial Officer of the Company.

16:08 EDT Lesaka repurchases 250,000 shares - Lesaka announced that it has repurchased approximately 250,000 of the company's common shares in May at a price of $3.26 per share.

16:06 EDT Bird Global announces one-for-25 reverse stock split - Bird Global "announced that its Board of Directors has approved a one-for-twenty-five (1/25) reverse stock split of its Class A common stock and Class X common stock. The reverse stock split was approved by Bird's stockholders at a Special Meeting of Stockholders held on May 18, 2023. The reverse stock split will become effective as of 5:00 pm Pacific Time today, May 18, 2023."

16:06 EDT Micron to introduce EUV technology to Japan - Micron announced it will be introducing extreme ultraviolet, or EUV, technology to Japan, tapping this sophisticated patterning technology to manufacture its next generation of DRAM, the 1-gamma node. Micron will be the first semiconductor company to bring EUV technology to Japan for production, with its Hiroshima fab playing a critical role in the company's development of the 1-gamma node. Micron expects to invest up to 500 billion yen in 1-gamma process technology over the next few years, with close support from the Japanese government, to enable the next wave of end-to-end technology innovation such as rapidly emerging generative artificial intelligence (AI) applications.

16:04 EDT Ross Stores reports Q1 SSS up 1%

16:01 EDT Analog Devices CFO Mahendra-Rajah to step down - Analog Devices announced that Prashanth Mahendra-Rajah, ADI's Executive Vice President & Chief Financial Officer, has informed the company that, after six years leading the finance operation, he will step down from his position to explore other opportunities. Prashanth will remain with ADI through the end of the fiscal year to ensure a seamless transition to new financial leadership. "I have greatly appreciated Prashanth's expertise and many contributions to ADI over the past years. During his tenure, we have experienced a period of extraordinary revenue and margin growth as we have scaled our global business, defined our industry-leading business model, and navigated an unprecedented supply and demand landscape," said ADI CEO & Chair, Vincent Roche. "I sincerely thank Prashanth for fostering strong investor community engagement, look forward to partnering with him during the transition, and wish him the best in his future endeavors." ADI has commenced a search to identify the company's next CFO. ADI is reaffirming its second quarter fiscal year 2023 financial outlook that was previously provided on February 15, 2023.

14:08 EDT Silence Therapeutics Plc - American Depository Share trading resumes

14:00 EDT Bausch + Lomb and Novaliq announce FDA approval of Miebo - Bausch + Lomb and Novaliq GmbH announced that the U.S. Food and Drug Administration has approved Miebo, formerly known as NOV03, for the treatment of the signs and symptoms of dry eye disease, or DED. Miebo is the first and only FDA-approved treatment for DED that directly targets tear evaporation, the companies stated. "Today's FDA approval of Miebo further advances DED treatment by addressing a significant unmet need for millions of people suffering with this disease. We are proud to bring to market the first and only prescription eye drop approved in the United States for the treatment of DED that directly targets evaporation. We expect to make Miebo commercially available in the second half of this year," said Brent Saunders, chairman and CEO, Bausch + Lomb.

13:38 EDT CDW trades busted after investors mistake symbol for CaliberCos - NYSE Arca Equities has ruled to bust all erroneous trades in CDW (CDW) executed on NYSE Arca Equities between 04:00:00 and 04:22:00 ET today, at or below $162.85. The ruling is not eligible for appeal. Shares of CDW traded for less than $7, or 96% below Wednesday's closing price of $173.25, driven by investors who bungled the company's ticker and mistook it for newly public alternative asset manager CaliberCos (CWD), according to Bloomberg. CDW shares ae little changed now at $174.04 while CaliberCos is up 23% to $7.39.

13:35 EDT Illinois Tool Works says M&A can extend long-term organic growth potential - Says "sweet spot" for M&A in past has been deals for companies in $200M-$500M annual revenue range. ITW executives continue to present during the company's investor day meeting.

13:10 EDT Barings Corporate Investors raises quarterly dividend by 14% to 32c per share - Barings Corporate Investors declared a quarterly dividend of 32c per share, payable on June 9, to shareholders of record on May 31. This represents an increase of 4c per share or 14.2% over the previous dividend of 28c per share and the third consecutive quarterly increase.

13:00 EDT Actinium CEO says Iomab could have 'multibillion-dollar' market opportunity

12:52 EDT Meta shares new details on AI projects, including AI training accelerator - Meta Platforms said in a blog post that it is now now executing on an ambitious plan to build the next generation of Meta's infrastructure backbone, specifically built for AI, and shared new details on projects related to AI. The company announced Meta Training and Inference Accelerator, its first in-house, custom accelerator chip family targeting inference workloads. MTIA provides greater compute power and efficiency than CPUs, and it is customized for our internal workloads. By deploying both MTIA chips and GPUs, we'll deliver better performance, decreased latency, and greater efficiency for each workload, the company said. "Meta's next-generation data center design will support our current products while enabling future generations of AI hardware for both training and inference," the Facebook parent added. "This new data center will be an AI-optimized design, supporting liquid-cooled AI hardware and a high-performance AI network connecting thousands of AI chips for data center-scale AI training clusters. It will also be faster and more cost-effective to build, and it will complement other new hardware, such as Meta's first in-house-developed ASIC solution, MSVP, which is designed to power the constantly growing video workloads at Meta." In addition, Meta said that its Research SuperCluster AI Supercomputer, which it believes is one of the fastest AI supercomputers in the world, was built to train the next generation of large AI models to power new augmented reality tools, content understanding systems, real-time translation technology, and more. "These AI-focused efforts enable us to take advantage of exciting new software advances like PyTorch 2.0," Meta noted. "The latest version of this open source AI framework, which was created by Meta in 2016 in partnership with the AI community, offers the same powerful, flexible, easy-to-use workflow. But it fundamentally changes and accelerates how the framework operates at the compiler level under the hood. With 2.0, PyTorch now provides faster performance and support for new features, like accelerated transformers and dynamic shapes." Reference Link

12:47 EDT Airspan Networks announces new financing and leadership changes - Airspan Networks announced that it has entered into a new financing agreement with affiliates of Fortress Investment Group. Under the agreement Airspan amended and restated the terms of its credit agreement with Fortress and certain other lenders to establish a new delayed draw term loan of $25M. In connection with the amendment and restatement, Airspan agreed to issue the lenders new common stock warrants to purchase 5,912,040 shares of its common stock at an exercise price of 1c per share. Airspan also modified the terms of its senior secured convertible notes to increase the principal amount to $52.5M and increase the interest rate to 10%. Airspan's Board also made certain changes to the company's senior management and Board of Directors. The Board appointed Glenn Laxdal, previously Airspan's President and COO, to serve as CEO, expanded Airspan's Board of Directors to ten directors, and appointed Laxdal to serve in the newly created Board position. Eric Stonestrom will now serve as Airspan's Executive Chairman. Eric Stonestrom, Executive Chairman of Airspan said, "We are continuing to make necessary changes to our operating model to focus the company and position it for the future. The Mimosa divestiture and debt restructuring provides the funding and sets the company up for its next phase of growth. We are excited to welcome Glenn to the Board and as Airspan's new CEO." Laxdal, who has served as Airspan's President and COO since January of 2022, said: "I am very excited to assume these new responsibilities at Airspan and to have financing to pursue our strategic vision for growing Airspan in the 5G broadband and enterprise private network markets."

12:22 EDT FCC votes to preserve spectrum between 12.2-12.7 GHz - The Federal Communications Commission said it "took a holistic approach to expanding use of over 1 gigahertz of prime mid-band spectrum in the 12 GHz band by ensuring stable spectrum access for current and next-generation satellite service while also empowering advanced terrestrial wireless services" The FCC adopted rules to preserve spectrum between 12.2-12.7 GHz for current and future satellite services. The FCC also proposed policies which would position the 12.7-13.25 GHz band to support flexible terrestrial wireless use, including 6G wireless services, the agency said in a statement. The outcome is a blow to Dish Network (DISH), which is working to set up a wireless broadband business, according to Bloomberg. Shares of Dish are down 1% to $6.80 in midday trading. Reference Link

12:14 EDT U.S. consumer spending on video gaming reached $4.1B in April, says Circana - Yesterday, Circana analyst Mat Piscatella said that April consumer spending on video game content, hardware and accessories in the U.S. reached $4.1B, a 5% drop when compared to a year ago. A 6% decline in April spending on video game content offset 7% growth in hardware. Year-to-date consumer spending on video game content, hardware and accessories fell 2% when compared to the same period in 2022, to $17.7B. Spending on video game content declined 6% in April when compared to a year ago, to $3.6B. All segments of content spending fell year-on-year in April except for non-mobile subscription content spending, which increased 2% versus April 2022. Video game hardware spending grew 7% when compared to YA, to $367M. This is the highest video game hardware spend for an April month since the $420M reached in April 2020. Double-digit percentage growth in both PS5 (SONY) and Switch (NTDOY) dollar sales offset declines on other platforms. Year-to-date hardware spending is now 18% higher when compared to the same period in 2022, at $1.8B. PlayStation 5 was the best-selling hardware platform in dollar sales during April, while Switch led the market in units sold. PlayStation 5 leads the 2023 hardware market year-to-date across both units and dollars. Accessories spending during April was flat when compared to a year ago, at $158M. The PlayStation 5 Dual Sense Edge Wireless Controller Black was the best-selling accessory in dollar sales for both April and 2023 year-to-date. Other companies in the space include Microsoft (MSFT), Tencent (TCEHY), Take-Two (TTWO), EA (EA), Activision Blizzard (ATVI), Ubisoft (UBSFY), and Capcom (CCOEY). Reference Link

12:07 EDT Nintendo's new 'Zelda' sells over 10M units globally in first three days - Nintendo said yesterday that "The Legend of Zelda: Tears of the Kingdom," which launched exclusively for Switch on May 12, has sold over 10M copies worldwide in its first three days, becoming the fastest-selling game in the history of the "Legend of Zelda" franchise. Reference Link

12:00 EDT Boot Barn falls -12.0% - Boot Barn is down -12.0%, or -$9.01 to $65.79.

12:00 EDT Bowlero falls -16.4% - Bowlero is down -16.4%, or -$2.31 to $11.75.

12:00 EDT MSG Entertainment rises 21.4% - MSG Entertainment is up 21.4%, or $6.79 to $38.52.

11:58 EDT Sanofi 'pleased' with Supreme Court's ruling on Amgen's asserted patent claims - Sanofi (SNY) said it is "pleased" with the United States Supreme Court's ruling in Amgen (AMGN) v. Sanofi et. al. The decision unanimously affirms the United States Federal Circuit Court's opinion that is favorable to Sanofi and Regeneron (REGN). Sanofi said: "This ruling reinforces our longstanding belief that Amgen's asserted patent claims are invalid and represents an unequivocal win for America's innovation economy, its scientists, and researchers. Most importantly, it is a win for patients who rely on the lifesaving discoveries made through years of research and investment by the biopharma community. The justices rejected an attempt to radically change the longstanding legal standard for patent validity under the enablement doctrine - a move that would have blocked progress for entire classes of molecules, deterred innovative competition, and led to potential increases of drug prices."

11:46 EDT F&M Bancorp raises dividend to 33c from 32c per share - The Board of Directors of Farmers and Merchants Bancshares, Inc., the parent of Farmers and Merchants Bank, declared a cash dividend of 33c per share of common stock, which will be paid on June 23 to shareholders of record on June 2. The 33c per share dividend is 1c greater than the most recent dividend paid in December 2022, the company noted.

11:35 EDT Nacco Industries raises quarterly cash dividend to 21.75c per share - NACCO Industries announced that the Board of Directors increased its regular cash dividend from 20.75c to 21.75c per share. The dividend is payable on both the Class A and Class B Common Stock, and will be paid June 15, 2023 to stockholders of record at the close of business on May 31, 2023. The new dividend is equal to an annual rate of 87c per share.

11:24 EDT Washington Attorney General announces $39.9M settlement with Google - Washington Attorney General Bob Ferguson announced Google will pay $39.9M to Washington state as a result of his office's lawsuit over "misleading location tracking practices." Google will also implement a slate of court-ordered reforms to increase transparency about its location tracking settings, Ferguson said in a statement. Ferguson's lawsuit against Google asserted that the company "deceptively led consumers to believe that they have control over how Google collects and uses their location data. In reality, consumers could not effectively prevent Google from collecting, storing and profiting from their location data." Reference Link

11:02 EDT Exela Technologies trading resumes

10:57 EDT Exela Technologies trading halted, volatility trading pause

10:52 EDT Cara announces NICE recommends Kapruvia for CKD-associated pruritus treatment - Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics announced earlier that England's National Institute for Health and Care Excellence, or NICE, has recommended Kapruvia for the treatment of moderate-to-severe CKD-associated pruritus in adult patients on hemodialysis. The decision follows authorization from the UK's Medicines and Healthcare products Regulatory Agency, or MHRA, in April 2022, the company stated. "We are pleased that Kapruvia will be available to CKD patients in England, Wales and Northern Ireland who are undergoing hemodialysis and suffering from moderate-to-severe CKD-associated pruritus. Together with VFMCRP, we are committed to bringing our first-of-its kind therapy to providers and patients around the world to help change the way pruritus is managed," said Christopher Posner, President and CEO of Cara Therapeutics.

10:48 EDT Equity Lifestyle trading resumes

10:46 EDT Equity Commonwealth trading resumes

10:37 EDT Equity Group Investments announces death of Sam Zell - Equity Group Investments announced that Sam Zell, chairman of Equity Group Investments, Equity LifeStyle Properties (ELS), Equity Residential (EQR), and Equity Commonwealth (EQC), died today at home due to complications from a recent illness. "The family of Equity companies mourns his loss," the group stated. "Sam lived life testing his limits and helping those around him do the same. He was a self-made entrepreneur, an industry creator and leader, a brilliant dealmaker, a generous philanthropist, and the head of a family he fiercely loved and protected. He had an unapologetic passion for life, a brilliant mind, a contagious wit, and a deep sense of civic responsibility and personal loyalty. All those who loved and learned from him will miss him terribly," added Scott Peppet, president of Chai Trust Company and Sam's son-in-law.

10:27 EDT Equity Residential announces death of Chairman Samuel Zell - Equity Residential announces the death of its Founder and Chairman, Samuel Zell, who died today at age 81. Zell founded the predecessor company to Equity Residential while a student at the University of Michigan and took it public in August 1993. Consistent with its "long-term succession planning process," the company has appointed David Neithercut as Chairman of the Board of Trustees effective immediately.

10:19 EDT Equity Lifestyle trading halted, news pending

10:18 EDT Equity Commonwealth trading halted, news pending

10:09 EDT Comscore selected as preferred partner for NBCUniversal's local ad currency - Comscore announced a partnership with NBCUniversal, in which NBCUniversal will be, for the first time, guaranteeing all local ad buys on Comscore measurement. The expanded partnership will support the transactional currency local advertisers will negotiate for inventory with NBCUniversal across its 31 local markets, plus 42 NBCU- and Telemundo-owned stations.

10:04 EDT Consensus Cloud Solutions partners with Hyland Software - Consensus Cloud Solutions announces a strategic partnership with Hyland Software to support the seamless integration of patient data between healthcare applications. eFax Corporate, by Consensus Cloud Solutions, is the leading digital cloud fax solution for healthcare. With HITRUST CSF certification, eFax Corporate ensures high availability, rapid delivery times, and unparalleled transmission security, making it a safer alternative to paper-based and on-premise faxing. Hyland Healthcare is a leading healthcare content services provider that enables thousands of organizations to deliver better experiences to the people they serve. The integration of these powerful technologies streamlines the exchange of patient information using a safe, secure, and regulatory-compliant digital cloud faxing solution with end-to-end encryption. This solution supports high volumes of both inbound and outbound faxes directly through Hyland's OnBase application as an integral part of the EHR workflows.

10:01 EDT Translate Bio announce first commercial shipment of BioXp NGS Library Prep Kit - Telesis Bio announced the first commercial shipment of its BioXp NGS Library Prep kit for Plasmid Sequencing. This NGS Library Prep kit enables on-demand and automated library preparation of plasmid DNA for use in next-generation sequencing applications.

10:00 EDT Lightspeed falls -11.4% - Lightspeed is down -11.4%, or -$1.70 to $13.18.

10:00 EDT Dole rises 9.3% - Dole is up 9.3%, or $1.11 to $13.04.

10:00 EDT Urstadt Biddle Properties Inc. rises 27.5% - Urstadt Biddle Properties Inc. is up 27.5%, or $4.21 to $19.55.

09:47 EDT Boot Barn falls -9.6% - Boot Barn is down -9.6%, or -$7.21 to $67.58.

09:47 EDT Bowlero falls -17.8% - Bowlero is down -17.8%, or -$2.50 to $11.56.

09:47 EDT Urstadt Biddle rises 17.1% - Urstadt Biddle is up 17.1%, or $2.90 to $19.85.

09:40 EDT CaliberCos Inc trading resumes

09:34 EDT Informa announces acquisition of Winsight, terms not disclosed - Winsight is to combine with London-based Informa. Informa acquired Winsight from HPS Investment Partners and the combination with Informa's existing B2B foodservice portfolio establishes a category-leading B2B business. Winsight CEO Mike Wood will continue to lead the business which will become part of the Informa Connect division. Headquartered in Chicago, Illinois, Winsight provides actionable information, market intelligence, professional events and media to the restaurant, noncommercial foodservice, convenience retailing and grocery industries. The Company offers a multi-channel portfolio of brands across research, data and analytics, events, websites, newsletters, and content marketing solutions. With nearly 3,000 customers, Winsight's solutions enable customers to measure and predict industry dynamics, drive engagement with target audiences, refine business development strategies, and create networking opportunities between buyers and sellers. Informa currently owns established foodservice media brands and tradeshows and intends to operate Winsight brands alongside these to strengthen its position in the Restaurant and Food space. Technomic, Winsight's data and insights business, will be Informa's first insights business dedicated to foodservice. Winsight will continue to operate business as usual through 2023 and will rebrand as Informa in the new year once integration planning is complete.

09:31 EDT Tecogen announces sale of chillers to Newark Penn Station - Tecogen announced the sale of two STx Chillers to NJ Transit for its historic Newark Penn Station. These chillers will replace the existing Tecogen chillers that have reliably served NJ Transit for over 25 years making the decision to upgrade an easy one. The new chillers will continue to be serviced by our Piscataway NJ service center.

09:27 EDT LanzaTech, Plastipak partner to produce PET resin made from waste carbon - LanzaTech and Plastipak Packaging produced PPKNatura, the world's first polyethylene terephthalate resin made from captured carbon emissions. The resin is suitable for food, personal care, and pharmaceutical packaging, as well as other non-packaging applications. PET is a polymer that is molded into plastic bottles and containers for packaging foods and beverages, personal care products, and many other consumer goods. PET resin comprises 30% monoethylene glycol traditionally derived from petroleum. PPKNatura leverages CarbonSmart(TM) MEG from LanzaTech's CCT process. It retains the technical properties of virgin fossil PET while carrying a lower carbon footprint. Thus, PPKNatura can be a used for traditional food and pharmaceutical grade packaging and other sensitive applications such as hot-fill, refillables, and applications where a low crystallinity is required. Non-packaging PET applications can also take advantage of this ground-breaking resin. PPKNatura resin reduces greenhouse gas emissions, and its production process does not require land or food resources. In addition, packaging made out of this material can be fully recycled at the end of its life, keeping the carbon in a circular material cycle.

09:20 EDT A2Z Smart Technologies forms Big Data team - A2Z Smart Technologies announced that as part of its transformation into a software, digital and data platform company which is focused on data based value added services it has established a dedicated Big Data team. The newly formed Big Data team will develop cutting-edge tools to identify, mine, and collect the rich data generated by Cust2Mate's smart carts platform. Leveraging advanced analytics, visualization techniques, and effective communication strategies, the team will provide a wealth of information collected and transformed into actionable intelligence. By offering data-as-a-service and tailored products, Cust2Mate aims to empower all stakeholders in the retail industry with valuable data-driven solutions.

09:19 EDT U.S. Army awards BAE Systems $72.5M PGM contract - U.S. Army Combat Capabilities Development Command Armaments Center DEVCOM AC has awarded BAE Systems a three-year contract for continued research and development efforts in the advancement of precision guided munitions, PGM, to support the Army's long-range precision fire modernization efforts. "We have invested heavily to innovate and develop a highly maneuverable long-range fires capability that will support Soldiers on the battlefield by providing lethality against high value targets," said Brent Butcher, vice president and general manager of Weapon Systems at BAE Systems. "We look forward to partnering with DEVCOM AC to continue to advance precision guided munitions and find the best long-range precision fires solution for the U.S. Army."

09:17 EDT Microbot announces Core Business Focus Program, cost restructuring plan - Microbot Medical announced its Core Business Focus Program and cost restructuring plan to continue enhancing the focus on its core technology while maximizing available resources to support it. This includes the focus on completing the validation and verification process and completing the planned first- in- human clinical cases with its LIBERTY Robotic Surgical System, both expected during the second half of 2023. As part of the Core Business Focus Program, and to maximize available resources, the Company will eliminate non-core technology expenses by terminating agreements relating to the TipCat, ViRob and CardioSert technologies. In addition, it executed several cost reduction initiatives to reduce expenses that are not directly supporting the Company's core technology, including reduction in positions not directly supporting the core LIBERTY technology and compensation reductions or restructurings for its leadership team and certain advisors. Further information about the Company's Core Business Focus Program and cost restructuring plan, as well as other information about the Company's results of operations and financial condition, can be found in its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023, filed with the Securities and Exchange Commission on May 17, 2023.

09:12 EDT Lucy Scientific Discovery announces partnership with TheraPsil - Lucy Scientific Discovery announces a partnership with TheraPsil to advance medical psilocybin access and research. The collaboration between Lucy and TheraPsil marks a significant milestone in expanding legal access to psilocybin for Canadian patients experiencing end-of-life distress and other serious medical conditions. Building upon TheraPsil's visionary initiative, Project Solace, the partnership aims to provide compassionate care while collecting real-world data to support the effectiveness and safety of psilocybin-assisted psychotherapy. Chris McElvany, Chief Executive Officer of Lucy Scientific Discovery Inc., expressed enthusiasm about the partnership, stating, "We are thrilled to collaborate with TheraPsil, as it provides us with a unique opportunity to bring natural psilocybin products to market in Canada. By leveraging TheraPsil's expertise and our shared commitment to patient well-being, we aim to gain valuable insights, build brand recognition, and positively impact the lives of individuals seeking alternative therapies."

09:09 EDT Fat Brands appoints Johnston as CMO, appoints two new presidents - FAT Brands announces the elevation of Jenn Johnston to the role of Chief Marketing Officer, CMO. Since the acquisition of Global Franchise Group in July 2021, Johnston has held the role of President of the Quick-Service Division at FAT Brands, overseeing brands including Round Table Pizza, Great American Cookies, Marble Slab Creamery, and Pretzelmaker. With Johnston's promotion to Chief Marketing Officer, Allison Lauenstein and David Pear will assume Brand President roles. Lauenstein will serve as Brand President of Great American Cookies, Marble Slab Creamery, and Pretzelmaker. Lauenstein brings over a decade of experience working with the respective brands, having previously served as Executive Vice President of Brand Operations and Marketing at Global Franchise Group. Pear will assume the role of Brand President at Round Table Pizza. Pear most recently served as Vice President of Strategic Initiatives at Desert De Oro Foods.

09:07 EDT LCNB Corp. to acquire Cincinnati Bancorp for $15.05 per share - LCNB Corp. (LCNB) and Cincinnati Bancorp (CNNB), the holding company for Cincinnati Federal, announced today that they have signed a definitive merger agreement whereby LCNB will acquire CNNB in a stock-and-cash transaction. When completed, the transaction will significantly increase LCNB's existing presence in the Cincinnati market and expand LCNB's community banking franchise across the Ohio River into the compelling Northern Kentucky market. Subject to the terms of the merger agreement, which has been approved by the Board of Directors of each company, CNNB shareholders will have the opportunity to elect to receive either 0.9274 shares of LCNB stock or $17.21 per share in cash for each share of CNNB common stock owned, subject to 80% of all CNNB shares being exchanged for LCNB common stock. As of March 31, CNNB reported 2,884,171 shares of common stock outstanding, as well as 296,350 options with a weighted average strike price of $10.65 per share. Any unexercised stock options of CNNB will be canceled in exchange for a cash payment at the spread value of $17.21 per share over the exercise price. Based on the LCNB closing share price as of May 17 the transaction consideration is valued at $15.05 for each CNNB share or approximately $43.7 million in aggregate which equates to a 108.9% multiple of tangible book value, a 32.3x multiple on LTM earnings and a core deposit premium of 2.3% as of March 31. The transaction consideration is subject to dollar-for-dollar downward adjustment if CNNB's adjusted shareholders' equity, as defined in the merger agreement, is less than $36.8 million as measured three business days immediately before the closing date.

09:05 EDT Wipro enters into five-year business partnership with ServiceNow - Wipro Limited (WIT) announced a five-year business partnership with ServiceNow (NOW) to invest in and bring new offerings to market that will empower clients to drive business transformation, overcome business challenges, and deliver greater value. The agreement expands on the two companies' existing partnership and is expected to help accelerate Wipro's goal of building a $1B business with ServiceNow by the end of 2026. As part of the partnership Wipro and ServiceNow will deliver joint clients process consulting, implementation, configuration, and managed services. The partnership will cover all global geographies and will initially focus on four key industries: Financial Services, Healthcare, Manufacturing, and Energy and Utilities.

09:03 EDT Adverum presents nonclinical data on Ixo-vec's Phase 2 development - Adverum Biotechnologies announced new nonclinical data supporting the use of ixoberogene soroparvovec at the American Society of Gene & Cell Therapy, ASGCT, 2023 Annual Meeting in Los Angeles, California. Ixo-vec is currently being evaluated in the Phase 2 LUNA trial in wet age-related macular degeneration, wet AMD. The data being presented at ASGCT are featured in an oral presentation on the identification of dose-dependent immune landscape signatures in nonhuman primates, an oral presentation of nonclinical data that supports the potential for staggered, bilateral dosing of Ixo-vec and a poster presentation evaluating Ixo-vec per cell vector genome biodistribution and mRNA expression in NHPs. "Our nonclinical data presented at ASGCT support the use of the human equivalent doses 2x10^11 vg/eye and 6x10^10 vg/eye doses being evaluated in the LUNA trial," stated Brigit Riley, Ph.D., chief scientific officer at Adverum. "It is well understood that gene therapy products cause dose-dependent inflammation regardless of serotype and route of administration. We were pleased to see that the Ixo-vec doses advanced in the LUNA trial can achieve therapeutic aflibercept levels in NHPs that improve the inflammation profile. These data support our development efforts around lower dose administration of Ixo-vec and enhanced prophylactic corticosteroid regimens being evaluated in LUNA. We look forward to sharing interim 14-week aflibercept protein levels for a percentage of the cohort in the LUNA trial in the third quarter of this year."

09:02 EDT Abbott's Assert-IQ cardiac monitor cleared by FDA - Abbott's Assert-IQ insertable cardiac monitor has received FDA clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats. Using Bluetooth technology, Abbott's Assert-IQ ICM is designed to remain connected to a transmitter - usually the person's own cell phone - where it checks heart rhythms every 20 seconds, transmitting results in real-time to the clinic's portal.

09:02 EDT AYRO opens pre-order queue for 2023 AYRO Vanish - Earlier this year, AYRO announced the release of the 2023 AYRO Vanish, the first "common core chassis" low-speed electric vehicle (LSEV) in the company's new strategic product roadmap. Today, AYRO is proud to announce that the Vanish is available for pre-orders for customers and fleet managers seeking quality, cost effective, and sustainable transportation solutions.

08:59 EDT Alibaba comments on spinoffs, capital raisings - Earlier, Alibaba said: "Our board of directors approved the commencement of a process to explore raising external capital for the Alibaba International Digital Commerce Group to support its development and growth. The capital raising will assist the business group to expand into new geographic markets, invest in new technologies, grow its consumer and supplier base, strengthen its management team and develop and enhance its products and services to its customers globally. Our board of directors approved the commencement of a process to explore an initial public offering of Cainiao Smart Logistics. The group provides supply chain, logistics and delivery services to consumers andmerchants that are customers of Taobao & Tmall Group and Alibaba International Digital Commerce Group, as well as third party customers. Alibaba Group holds a 67% equity interest in Cainiao Smart Logistics. Our board of directors approved the commencement of a process to execute an initial public offering of Freshippo (Hema), our new retail business. We expect the initial public offering will be completed in the next 6 to 12 months."

08:58 EDT Conduent introduces Rapid Assistance payment solution - Conduent announced Rapid Assistance, a new transformational payment solution. This solution can dramatically speed up the ability of government agencies and non-profit organizations to securely deliver funds to individuals. When needs are urgent, agencies now can dispatch aid to those impacted by natural disasters and other crises in a matter of minutes, rather than in days or weeks.

08:52 EDT Walmart says supply chain is in much better place versus last year - Says in Q2 focused on getting merchandise costs down, pickup and delivery execution, expense management and inventory management. Says wants operating profit growing faster than sales. Says believes ROI will increase this year. Says macro-pressures on the consumer have intensified. Says year is off to a good start. Says supply chain is in much better place compared to last year. Says mix issue between food consumers and general merchandise. Says China had very strong quarter. Comments taken from Q1 earnings conference call.

08:41 EDT GE announces Rahul Ghai to become CFO September 1, succeeding Happe - GE announced a Chief Financial Officer transition. Rahul Ghai will become Senior Vice President and Chief Financial Officer of GE effective September 1, succeeding Carolina Dybeck Happe. Mr. Ghai will assume this role in addition to his current responsibilities as Chief Financial Officer of GE Aerospace, which he has held since August 2022. Dybeck Happe will continue as an SVP of GE for a period of time to assist with the transition and continued work to prepare for separation readiness ahead of the planned GE Vernova spin-off. GE Chairman and CEO and GE Aerospace CEO H. Lawrence Culp, Jr., said, "Since Rahul joined GE Aerospace, we have benefited greatly from his leadership, including his wealth of experience as a public company CFO and with the spin-off process. This is the right time to make this change as GE progresses toward launching GE Vernova and GE Aerospace as standalone businesses, and I look forward to partnering with Rahul in this additional capacity."

08:40 EDT Bausch Health announces publication on OraPharma's ARESTIN microspheres - Bausch Health Companies and its oral health care business, OraPharma, announced the publication of a new study, which showed that ARESTIN microspheres, 1mg decreased certain pathogenic burdens, also known as infection burdens, in adults with periodontitis when applied immediately after scaling and root planning and again at a three-month reapplication, versus SRP alone. ARESTIN is an FDA-approved antibiotic applied locally to gum pockets in adults with periodontitis following an SRP procedure and is used as part of an overall oral health program. ARESTIN should not be used in people who are allergic to minocycline or tetracyclines. The investigator-initiated trial, sponsored in part by Bausch Health, and conducted by researchers from the University of Minnesota School of Dentistry, appeared today in the Journal of Periodontology. The study showed minocycline application immediately after initial SRP and reapplication at 3-months after SRP decreased certain key pathogens and may have contributed to improvements in probing depth, clinical attachment loss, bleeding on probing and gingival index compared to SRP alone. Since the pivotal trial, there was a gap in the literature on whether minocycline HCI microspheres, 1mg reduced specific periodontal pathogens. This study identified that the administration of minocycline HCI microspheres, 1mg did significantly decrease specific periodontal pathogens. The objective of the study entitled, Effect of Scaling and Root Planing With and Without Minocycline HCl Microspheres on Periodontal Pathogens and Clinical Outcomes: A Randomized Clinical Trial, was to determine if minocycline HCl plus SRP contributed to the improvement of certain clinical measures commonly seen in patients with gum disease. A secondary endpoint was to determine if minocycline microspheres HCl with SRP lowered specific pathogens responsible for periodontitis compared to SRP alone. Saliva and clinical outcomes were collected for both groups at baseline before SRP, 1-month reevaluation, and at 3 and 6-month periodontal recall. Minocycline microspheres were delivered to pockets greater than or equal to5 mm immediately after SRP and immediately after the 3-month periodontal maintenance. This study reported that of the 11 pathogens that play an instrumental role in periodontitis, there were six periodontal pathogens that had a statistically significant decrease at 1-month and four periodontal pathogens with a statistically significant decrease at the 6-month periodontal maintenance versus the SRP group alone. This study also reported that minocycline HCI plus SRP achieved greater improvement for probing depth, bleeding on probing, gingival index, and improvement in clinical attachment loss by the six-month periodontal maintenance versus SRP alone. Limitations of the study include the lack of a blinded examiner for clinical outcomes and lack of patient-reported outcome measures. The principal investigator collected saliva, recorded clinical measures and provided treatment for both groups. The participants in this study were predominantly from the Midwestern region, Caucasian and over the age of 50 years old, which does not represent the general population of individuals with periodontitis.

08:37 EDT SteraMist unveils new website to enhance user experience - TOMI Environmental Solutions announced the launch of its updated website, now accessible through the new domain name steramist.com. The refreshed website offers a modern, user-friendly design and streamlined navigation, providing visitors with easy access to essential information about SteraMist products and services. The updated website features a sleek and professional design, highlighting SteraMist's advanced disinfection technology and its many applications in various industries. Visitors can learn about the benefits of using SteraMist's patented ionized Hydrogen Peroxide technology, which has been proven to kill harmful pathogens, including COVID-19, with unmatched efficacy and efficiency.

08:35 EDT Micron to introduce EUV technology to Japan - Micron announced it will be introducing extreme ultraviolet, or EUV, technology to Japan, tapping this sophisticated patterning technology to manufacture its next generation of DRAM, the 1-gamma node. Micron will be the first semiconductor company to bring EUV technology to Japan for production, with its Hiroshima fab playing a critical role in the company's development of the 1-gamma node. Micron expects to invest up to 500 billion yen in 1-gamma process technology over the next few years, with close support from the Japanese government, to enable the next wave of end-to-end technology innovation such as rapidly emerging generative artificial intelligence (AI) applications.

08:34 EDT Dolby achieves milestone of 500th theatrical film in Dolby Vision, Dolby Atmos - Dolby Laboratoriescelebrate a new partnership milestone with the upcoming release of Mission: Impossible - Dead Reckoning Part One, marking the 500th theatrical film confirmed in both Dolby Vision and Dolby Atmos. The film, from Paramount Pictures and Skydance, will be released in theatres on July 12th.

08:33 EDT Bit Digital expands mining operations into Iceland - Bit Digital has finalized an agreement to expand the company's bitcoin mining presence into Iceland. Following this agreement, Bit Digital will have mining operations in three countries: the U.S., Canada, and Iceland. Bit Digital has finalized a two-year agreement with GreenBlocks for approximately 8.25 MW of incremental hosting capacity at a facility in Reykjanesbaer, Iceland. The company will fill the capacity with approximately 2,000 S19j Pro+ and 500 S19 mining units that were recently purchased for approximately $3.6M. The mining units are expected to be delivered to the facility by the end of May 2023. GreenBlocks, based in Iceland, focuses on the use of renewable energy in mining and validation of blockchains.

08:31 EDT Siemens, TrendMiner partner to drive operational performance, sustainability - TrendMiner and Siemens AG are excited to announce their strategic partnership aimed at helping industrial companies achieve digitalization goals while maintaining a competitive advantage. TrendMiner is now a recommended solution for distributed process controller SIMATIC PCS 7 users. The software has been included in the PCS 7 product catalog as an official add-on for applying advanced analytics to time-series data in its process historian. The integration will soon be extended to support the analysis of batch data for a variety of operational improvements, such as cycle-time reduction and batch-quality optimization. The TrendMiner integration will also allow engineers to add batch data in the software's ContextHub for deeper process insights.

08:28 EDT Allstate announces catastrophe losses for the month of April of $799M - The Allstate Corporation announced estimated catastrophe losses for the month of April of $799M or $631M, after-tax. April month catastrophe losses include 12 events estimated at $872M with approximately 60% of the losses related to two wind and hail events, partially offset by favorable reserve reestimates for prior events. During the month of April, the Allstate brand implemented auto rate increases of 8.6% across 13 locations, resulting in total brand premium impact of 1.6%. "Allstate continued to implement significant auto insurance rate actions as part of our comprehensive plan to improve profitability. Since the beginning of the year, rate increases for Allstate brand auto insurance have resulted in a premium impact of 3.3%, which are expected to raise annualized written premiums by approximately $862M," said Jess Merten, Chief Financial Officer of The Allstate Corporation. Our implemented auto rate exhibit has been posted on allstateinvestors.com.

08:24 EDT Biomerica announces inFoods IBS test validated for use with finger stick - Biomerica announced a significant advance in the management of irritable bowel syndrome, IBS. The inFoods IBS diagnostic test has now been validated for use with finger stick patient whole blood samples simplifying sample collection and facilitating wider access to the test. With this new finger stick blood collection option, any trained medical professional in the doctor's office can collect the patient's blood sample during their office visit and forward the sample to the Lab for processing. "This is a significant step forward for patients, healthcare providers, and the broader medical community," said Zackary Irani, CEO of Biomerica. "By enabling the use of finger stick whole blood samples, we're making our personalized IBS therapy more convenient and easier than ever. This process reduces patient discomfort, and facilitates wider access to the inFoods IBS test, allowing healthcare providers in a variety of settings to efficiently use inFoods IBS and initiate appropriate treatment plans."

08:22 EDT Microchip releases MPLAB-ICD 5, MPLAB PICkit 5 debuggers/programmers - As programming and debugging continue to be vital-and manually time consuming-processes for embedded designers, Microchip Technology has launched two tools offering fast, affordable and convenient solutions. The new MPLAB ICD 5 and MPLAB PICkit 5 in-circuit debuggers/programmers both feature remote programming capabilities for an enhanced user experience. The MPLAB ICD 5 in-circuit debugger/programmer offers advanced connectivity and power options for developers of designs based on PIC, AVR and SAM devices and dsPIC Digital Signal Controllers. Because it reduces the need for power cables, this development tool can be used in environments where efficient use of space is necessary. Powered by a USB Type-C connection to a PC or Power over Ethernet+, the MPLAB ICD 5 in-circuit programming and debugging tool is fast, flexible and convenient. PoE+ allows the device to be powered by the same cables that are used for data communication without the need for additional power cords. In addition to the flexibility that PoE+ offers, the Ethernet connection allows for remote development and isolation from environmental conditions.

08:21 EDT Mustang Bio announces strategic manufacturing partnership, portfolio updates - Mustang Bio announced a strategic update, including anticipated milestones for 2023. Mustang intends to optimize the allocation of its resources and focus on MB-106, MB-109, and in vivo CAR T platform technology. Additionally, Mustang announced a partnership with uBriGene Biosciences, the U.S. subsidiary of uBriGene Group, a leading cell and gene therapy contract development and manufacturing organization, which includes the sale of the Company's development, manufacturing and analytical testing facility in Worcester, Massachusetts to uBriGene. Under the terms of an asset purchase agreement between Mustang and uBriGene, uBriGene will acquire Mustang's commercial-scale cell and gene therapy manufacturing facility in Worcester, Massachusetts, for a total consideration of $11 million. This consideration includes $6 million payable upfront plus an additional $5 million payable upon Mustang raising $10 million in gross proceeds from equity raises following the closing of the transaction. The closing of the transaction is subject to the satisfaction of certain conditions, including approval of transfer of the Company's lease to uBriGene by the owner of the building and the acceptance of offers of employment with uBriGene or its affiliates by certain key current Mustang employees. Subject to satisfaction of conditions, the Company expects the transactions to close in June 2023. Subject to closing, the parties will enter into a manufacturing supply agreement, under which uBriGene will manufacture Mustang's lead product candidates, including continuing to support MB-106 manufacturing for the ongoing multi-center Phase 1/2 trial.

08:18 EDT Duos Technologies Group announces latest railcar AI detection model - Duos Technologies Group announced the release of its latest key railcar artificial intelligence detection model for use with the Company's Railcar Inspection Portal solution. The new algorithm covers end-of-car cushion inspection, a condition which can potentially lead to derailments. "We are continuing to advance rail safety standards with the development of specialized AI models capable of identifying defects that can cause real problems for rail operators, including derailments," said Duos CEO Chuck Ferry. "This new 'Head of Cushioning Unit Condition' model is already in use at one of our Class 1 customers, and we've demonstrated meaningful results in identifying validated defects. As we expand the breadth of detection models for our RIP systems, customers have shown a clear desire to add this greater level of coverage. We plan to continue expanding our AI development work and expect to have more than 50 models available in our catalogue by year end."

08:18 EDT HTG Molecular to highlight advantages of its drug discovery engine at 2023 BIO - HTG Molecular Diagnostics announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization, BIO, International Convention and will host in-person meetings during the remaining days of the June 5 - 8, 2023 event in Boston, MA. "We have demonstrated that our innovative approach to drug discovery allows for the progression of molecules from target to drug candidate in approximately 12 months, with the added benefit of developing much deeper knowledge about the biological responses in diseased cells at earlier stages in discovery. Further, the data that our team has generated in these studies serve as a tangible demonstration of the power of the drug discovery engine we have built," said Dr. Barat. "I look forward to the opportunity to share the power of this drug discovery engine with potential partners and customers at the BIO International Convention and to continue to help others see how our technology can be used to make more well-informed selection choices earlier in the drug discovery process and improve the chances for success in development when compared to existing drug discovery and development approaches."

08:16 EDT Oxford Lane estimates NAV per share $4.56-$4.66 as of April 30 - Management's unaudited estimate of the range of the NAV per share of our common stock as of April 30, 2023 is between $4.56 and $4.66. This estimate is not a comprehensive statement of our financial condition or results for the month ended April 30, 2023. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending June 30, 2023 may differ materially from this estimate, which is given only as of April 30, 2023. As of April 30, 2023, the Company had approximately 173.6 million shares of common stock issued and outstanding.

08:14 EDT Mobiquity Technologies announces the launch ElecTech - Mobiquity Technologies announces the launch of ElecTech, an AI-powered programmatic platform destined to redefine political advertising. Harnessing the power of first-party data and advanced artificial intelligence, ElecTech provides unrivaled precision in voter targeting and message optimization. "With ElecTech, we are delivering a platform that incorporates advanced AI algorithms, dynamic creative optimization, and robust audience segmentation techniques. We have designed it to be a one-stop solution for modern political campaigns that want to connect with voters on a deeper and more personalized level," said Dean Julia, CEO of Mobiquity Technologies.

08:12 EDT Wearable Devices to enable new user experience for mobile games - Wearable Devices announced the successful completion of testing for a gesture-based control system to provide mobile gamers with a touchless gaming experience across mobile gaming devices. The proof of concept was conducted using the Mudra Band, the Company's flagship consumer product. "With mobile games accounting for approximately 50% of global game revenues in 2022, this market represents a significant opportunity for our technology, and we're excited to deliver a gesture-based user experience that was previously available only for stationary gaming consoles," commented Mr. Offir Remez, Executive Vice President of Business Development at Wearable Devices Ltd. "We believe a major part of the gaming experience is lost due to the limitations of the touchscreen and adding gesture-based interactions to mobile games will bring more excitement, fun and joy to gameplay."

08:11 EDT Rev Group appoints Mark Skonieczny CEO - REV Group announced the appointment of Mark Skonieczny as President and Chief Executive Officer, effective immediately. Previously, Mr. Skonieczny had served as Interim CEO and Chief Financial Officer. Mr. Skonieczny joined the Company's Board in January 2023 and will continue to serve as a director. The company has initiated a comprehensive search for a new CFO. Prior to joining REV Group, Skonieczny held positions as Vice President and Corporate Controller of Adient and spent 17 years at Johnson Controls in a variety of financial roles including Vice President of Corporate Development, Vice President of Finance, Global Aftermarket-Power Solutions, Vice President of Finance, Middle East, Latin America and NA Systems-Building Efficiency, and Assistant Corporate Controller.

08:10 EDT PDS Biotechnology completes enrollment in VERSATILE-002 Phase 2 trial - PDS Biotechnology announced the completion of enrollment in the immune checkpoint inhibitor naive group of its VERSATILE-002 Phase 2 trial for the treatment of recurrent or metastatic human papillomavirus 16-positive head and neck cancer. "Completing enrollment in the ICI naive arm is an important milestone in the VERSATILE-002 Phase 2 trial and the ongoing development of PDS0101 in combination with KEYTRUDA(R) as a potential treatment for recurrent and/or metastatic HPV16-positive head and neck cancer," said Dr. Lauren V. Wood, Chief Medical Officer of PDS Biotech. "HPV-driven HNSCC is a growing problem, and there is a large unmet medical need to develop an HPV-targeted immunotherapy. Preliminary data reported at ASCO 2022 and highlighted at our October 2022 Head and Neck Cancer KOL Roundtable suggest that PDS0101 in combination with KEYTRUDA(R) may lead to improved outcomes in ICI naive, recurrent or metastatic HNSCC patients. We now look forward to reporting updated data from the VERSATILE-002 trial at ASCO 2023 as the next step towards a planned global confirmatory randomized, controlled trial investigating the combination of PDS0101 and KEYTRUDA(R) in this same patient population."

08:09 EDT Creative Medical Technology's StemSpine shows positive efficacy, safety results - Creative Medical Technology announced "positive" top line pilot study results for the StemSpine procedure using AlloStem to treat chronic lower back pain. The data demonstrated significant efficacy and no serious adverse events using the StemSpine ultrasound guided non-surgical procedure for treating chronic lower back pain. The StemSpine procedure using AlloStem resulted in a greater than 90% reduction in narcotic usage, greater than 80% reduction in pain score, and greater than 50% reduction in the Oswestry Score in the treated patients. No patients required re-dosage or surgical intervention at the primary end point of six months and there were no safety related concerns.

08:08 EDT Replimune Group enters transition, separation agreement with CFO Jean Franchi - Replimune has entered into a transition and separation agreement with Jean Franchi, who has informed the company of her intention to leave effective June 2, 2023. Jean will continue to work with the Company as an advisor until December 31, 2023. Andrew Schwendenman, Vice President of Finance, will assume the role of Chief Accounting Officer. Philip Astley-Sparke will serve as interim CFO while the search for a replacement is conducted.

08:07 EDT Replimune Group expects cash to fund operations into 2H25 - As of March 31, 2023, cash, cash equivalents and short-term investments were $583.4 million, as compared to $395.7 million as of fiscal year end March 31, 2022. The increase in cash as of March 31, 2023 reflects net proceeds from equity offerings and the initial debt tranche resulting in approximately $311.4 million of year-to-date financing inflows partially offset by cash utilized in operating activities in advancing the Company's clinical development plans. Based on the current operating plan, the Company believes that existing cash, cash equivalents and short-term investments, as of March 31, 2023, will enable the Company to fund operations into the second half of calendar year 2025.

08:06 EDT TuSimple to delay filing quarterly report on Form 10-Q - TuSimple announced that as previously disclosed in the TuSimple Holdings Notification of Late Filing on Form 12b-25, filed with the Securities and Exchange Commission on May 11, 2023, the company has determined that it is unable, without unreasonable effort or expense, to file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2023 by the prescribed due date because the company requires additional time to finalize the Form 10-Q in light of thecCompany's recent engagement of a new independent registered public accounting firm for the fiscal year ending December 31, 2022, as previously disclosed in the company's Current Report on Form 8-K filed with the SEC on the same date.

08:04 EDT Light & Wonder proposes to acquire remaining 17% of SciPlay for $20.00 per share - Light & Wonder (LNW) announced that it has submitted a proposal to the board of directors of SciPlay Corporation (SCPL) under which Light & Wonder would acquire the remaining 17% equity interest in SciPlay that it does not currently own for $20.00 per share in an all-cash transaction valued at $422M. Following the transaction, SciPlay would become a wholly owned subsidiary of Light & Wonder.

08:02 EDT TuSimple restructures U.S. operations, announces 30% global workforce reduction - TuSimple announced a restructuring plan for its U.S. operations that is intended to enable the company to continue maturing its technology while preserving the company's balance sheet. The company also announced it is no longer seeking strategic alternatives for its Asia Pacific subsidiaries. In light of current market conditions, today TuSimple announced it is reorganizing its U.S. operations and better aligning staffing levels with the company's goals. This includes an approximately 30% reduction to TuSimple's global workforce. The reduction in workforce will only impact TuSimple locations within the U.S. Rooted in the tenets of the "V-model," an industry standard for developing complex systems, the new organizational structure for U.S. operations is designed to prioritize validation and testing of the company's Level 4 autonomous technology, and to improve organizational accountability and reporting lines. The restructuring is expected to lead to approximately $12 million to $13 million in one-time charges, consisting primarily of severance and WARN Act-related expenses, and result in an expected annual cash compensation expense savings of approximately $64 million to $68 million. Including the restructuring in December 2022, total annual cash compensation savings are expected to be in excess of $120 million. "As we relaunch TuSimple, we have taken a variety of factors into consideration including further deterioration of global economic growth, significantly reduced capital availability in the self-driving industry and redundant hardware availability," said Cheng Lu, president and CEO of TuSimple. "Given these factors, we believe this restructuring, while difficult, aligns our capital spend with the pace of overall industry readiness and improves our long-term competitive position. These decisions are not made lightly as they impact many of our colleagues. Our company would not be where it is today without their contributions. For that, they have our utmost gratitude."

07:45 EDT Nextech3D.ai receives $2M in cash from FinTech Ratio Tech - Nextech3D.AI has received an initial $2,000,000 cash infusion from FinTech Ratio Tech representing zero-dilutive funding. The $2,000,000 in cash was paid against future invoices that the Company has contracts for but has not yet been paid for. The Company views this new relationship with Ratio as a substantial long-term positive for shareholders as it provides almost unlimited access to a non-dilutive capital source for its purchase orders, some of which are contracts with 12-36 month terms. This new access to non-dilutive capital on these long-dated purchase orders has greatly enhanced Nextech3D.ai's financial flexibility. The Company has not issued any security or securities including common shares, options or warrants in connection with this $2,000,000 cash infusion. The interest rate is prime plus 3.5%.

07:40 EDT Auddia announces launch of podcasts in Android version mobile app faidr - Auddia announced that it has released podcast-listening functionality in the Android version of its flagship mobile app, faidr. Podcasts were added to the Company's iOS product in March of this year, along with faidrRadio, its exclusive content programming within the app. The Company now moves to launch a new user interface for faidr. "We are excited that our Android users can take advantage of commercial-free AM/FM alongside their favorite podcasts," said Auddia's CEO Michael Lawless. "And we're looking forward to rolling out enhanced podcasting features later in the year across both operating systems to further differentiate this feature." By early Q3, Auddia will have completed the integration of podcast listening, faidrRadio exclusive content, and a new user interface into the faidr app across both the iOS and Android platforms.

07:38 EDT Cognition Therapeutics announces Phase 1b trial results of CT1812 - Cognition Therapeutics announced that a manuscript entitled, "A Phase 1b Randomized Clinical Trial of CT1812 to Measure Abeta Oligomer Displacement in Alzheimer's Disease Using an Indwelling CSF Catheter" has been published in the journal, Translational Neurodegeneration. "By evaluating hourly changes in beta amyloid oligomer concentrations in the cerebrospinal fluid of individuals with mild-to-moderate Alzheimer's disease, we were able to observe the impact of CT1812 target engagement," stated Mary Hamby, PhD, VP of research. "Data from the Phase 1b SNAP study mirror findings from our preclinical studies showing Abeta oligomer displacement from neurons in culture and into the CSF in transgenic mice. We believe these findings provide confirmatory evidence that CT1812 engages its target, the sigma-2 receptor, and through this interaction causes rapid displacement of Abeta oligomers from their binding sites on synapses into the CSF." Findings from the SNAP study demonstrate that a single oral dose of CT1812 rapidly displaces Abeta oligomers from synapses. This was shown by a marked temporal increase in CSF Abeta oligomer levels after a single dose of CT1812. In comparison, no change was observed in Abeta oligomers levels following administration of placebo. In this study of three individuals with Alzheimer's disease, CT1812 was well-tolerated, and no serious adverse events were related to study medication, but instead were due to the lumbar puncture procedure for the indwelling catheter used for CSF sampling.

07:36 EDT Whitestone REIT elects new board member Buthman - Whitestone REIT announces the addition of Julia Buthman to the Company's Board of Trustees, elected May 12th at Whitestone's annual shareholder's meeting. Buthman is a seasoned investment professional with more than 35 years of investing in senior debt, subordinated debt and structured equity. Buthman joins Whitestone's existing board members, all reelected at the annual meeting.

07:35 EDT FibroGen announces results from Phase 3 study of roxadustat - FibroGen and its subsidiary, FibroGen Medical Technology Development announced positive topline data from Company's Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for non-myeloid malignancies in China. Roxadustat demonstrated non-inferiority compared to recombinant erythropoietin alfa on the primary endpoint of change in hemoglobin level from baseline to the average level during weeks 9-13. In the preliminary safety analysis, the adverse event profile of roxadustat was generally consistent with previous findings and supportive of a positive benefit risk in this patient population. "Roxadustat is a promising potential new oral drug for treating chemotherapy-induced anemia, which complicates the treatment of many cancer patients," said Mark D. Eisner, MD, MPH, Chief Medical Officer, FibroGen. "Chemotherapy-induced anemia remains an unmet medical need in China, and we believe that roxadustat has potential to improve the lives of these patients."

07:34 EDT FreightCar America appoints Randall as Chief Operating Officer - FreightCar America announced the appointment of Nicholas Randall as the Company's Chief Operating Officer, COO, effective June 26, 2023. Randall will report to James Meyer, President and Chief Executive Officer. Randall has over 20 years of global experience working in, and leading, engineering and manufacturing operations at world class companies. He currently leads a division of aerospace company Precision Castparts Corporation.

07:32 EDT Orgenesis announces collaboration agreement with SCTbio - Orgenesis has signed a collaboration agreement with SCTbio, a full-service contract development and manufacturing organization, CDMO, specializing in cell-based therapy and viral vectors. The goal of the collaboration is to open new point-of-care sites within the Czech Republic and leverage SCTbio's GMP facility for the production of lentivirus vectors to support Morgenesis' POCare worldwide customers, including use in CAR-T cell and gene therapies, CGTs. Vered Caplan, CEO of Orgenesis, commented, "This partnership reflects our commitment to helping bring potential breakthrough cell therapies to market in a cost-effective, high-quality, and scalable manner. We look forward to teaming with SCTbio to expand our POCare CGT production services to the region, as well as leveraging their lentiviral vector production as a key element supporting our CAR-T customers in the EU."

07:24 EDT Idaho Strategic completes surface mining of Jumbo Vein - Idaho Strategic Resources announced the recent completion of surface mining of the high-grade Jumbo Vein and plans for exploration of the Jumbo Vein by drifting along the vein from the pit bottom. Surface mining of the Jumbo Vein resulted in 4,000 tonnes of ore at a grade of 17.3 grams per tonne gold. IDR Vice President Grant Brackebusch commented, "Following completion of surface mining, we plan to advance an underground drift to the south along the vein towards a high-grade drill intercept from 2011 which is at about the same elevation as the bottom bench - 1069 m. As previously mentioned, it is worth noting that the sample from the Jumbo Vein where it enters the pit wall was 0.6 meters wide and assayed 152 gpt gold."

07:23 EDT Hudbay Minerals, Copper Mountain file a joint management information circular - Hudbay Minerals (HBM) and Copper Mountain Mining (CPPMF) announce that they have filed a joint management information circular dated May 15, 2023 and related meeting materials in connection with their respective special meetings of shareholders scheduled to be held on June 13, 2023. The purpose of the Meetings is to seek approval for certain matters in connection with their previously announced transaction whereby Hudbay will acquire all of the issued and outstanding common shares of Copper Mountain, pursuant to a court approved plan of arrangement under the Business Corporations Act. Under the terms of the Transaction, each Copper Mountain shareholder will receive 0.381 of a Hudbay common share for each Copper Mountain common share held, representing a 23% premium to Copper Mountain shareholders based on Hudbay's and Copper Mountain's 10-day volume-weighted-average share prices on April 12, 2023. The Transaction requires the approval of at least 66 2/3% of the votes cast by the shareholders of Copper Mountain, a simple majority of the votes cast by shareholders of Copper Mountain excluding the votes required to be excluded by Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions, and a simple majority of the votes cast by shareholders of Hudbay. In addition to shareholder approvals, the Transaction is subject to final court approval and the satisfaction of certain other customary closing conditions for transactions of this nature. The Toronto Stock Exchange has conditionally approved the listing of the Hudbay common shares to be issued in connection with the Transaction, and the requisite regulatory approval for the Transaction under the Competition Act has been obtained. It is currently anticipated that the effective date of the Transaction will occur in late June 2023.

07:21 EDT PyroGenesis announces receipt of $2M payment under existing Drosrite contract - PyroGenesis Canada announces that it has received a payment of $1.5 million under the Company's existing CA$25+ million Drosrite contract. A balance of $8 million remains to be received under the contract. "We trust that this payment will allay any concerns that some may have had with respect to the collectability of this receivable", said Mr. P. Peter Pascali, CEO and President of PyroGenesis. "The payment announced today was made in accordance with a continuously revised payment schedule geared to better align the pressures on the end-client's operating cash flows created by increased business opportunities. While there have been some delays, which were communicated to us in advance, the Company is in agreement with the general strategy being implemented by the client and its end-client. PyroGenesis believes that this relationship will lead to increased business opportunities as we cross sell our downstream and upstream business lines with this end-client and potentially with others in the region. Discussions in this regard have taken place, and continue to take place, with the client and the end-client. Although we anticipate receiving future payments based on the revised schedule being worked out, we recognize the possibility of future periodic payment delays due to unforeseen circumstances beyond our control. Nevertheless, based on the information we have, we view this project as a steppingstone to generating more business opportunities in the Middle East region."

07:19 EDT Marimaca Copper announces updated MRE for Marimaca Oxide Deposit - Marimaca Copper announces an updated Mineral Resource Estimate, MRE, for the Marimaca Oxide Deposit located in the Antofagasta region of northern Chile. "The 2023 MRE represents the culmination of an exceptionally successful two years of infill drilling at the Marimaca Oxide Deposit led by Sergio Rivera and his team. We are very pleased with our conversion ratio of Inferred Resources to Measured and Indicated categories, and today's result drives significantly improved confidence in the geological model and understanding of the Marimaca ore body. The M&I resource estimate at the MOD now stands at approximately 900,000 tonnes of contained metal, and this will support the assessment of a larger operation in terms of copper cathode production and mine life extension during the Definitive Feasibility Study.... We continue to progress rapidly forward with development workstreams at the MOD including preparation for our permitting submissions and the Feasibility Study. Additionally, the first phase of the 2023 sulphide exploration program has been completed with assays pending and results expected in the near term."

07:18 EDT Orchard Therapeutics presents data from research programs at ASGCT - Orchard Therapeutics presented new data from the company's hematopoietic stem cell gene therapy research pipeline targeting larger indications at the ongoing 26th Annual Meeting of the American Society of Gene and Cell Therapy, ASGCT, in Los Angeles. Presentations include preclinical proof-of-concept data from OTL-104, the company's investigational HSC gene therapy for the treatment of nucleotide-binding oligomerization domain containing protein 2 Crohn's disease, as well as in vivo preclinical data demonstrating the development of functional CAR-Treg cells from genetically engineered HSCs. Both programs were designed and developed in Orchard's own research laboratories utilizing the company's proprietary HSC gene therapy platform. OTL-104 Preclinical Data Summary: Using established in vitro and in vivo models of NOD2 deficiency, including NOD2 knockout mice and HSC-derived macrophages from Crohn's patients with biallelic NOD2 mutations, Orchard researchers evaluated the safety and efficacy of HSC gene therapy in restoring NOD2-dependent immune responses. These results confirm the negative impact of NOD2 deficiency in primary immune activation and support the therapeutic potential of HSC gene therapy to provide long-term correction of NOD2 Crohn's disease. Work to evaluate OTL-104's ability to correct an induced NOD2 knockout mouse model of ileitis is currently ongoing. The company expects to commence IND- and CTA-enabling studies in the second half of 2023, with a potential filing now anticipated in the first half of 2025. HSC CAR-Treg cell Technology Preclinical Data Summary: Data from transplanted mice show that the preferential expression of CAR in HSC-derived regulatory T cells in vivo does not significantly alter the development, phenotype or function of these suppressive immune cells. Also, the functionality of the CAR receptor is demonstrated when HSC-derived CAR-Tregs can be activated ex vivo by exposure to a CAR-specific ligand, producing the immunosuppressive cytokine IL-10. The company will continue to advance its preclinical research activities aimed at further demonstrating the feasibility and applicability of its HSC CAR-Treg cell technology.

07:15 EDT Aslan Pharmaceuticals doses first patient in Phase 2a trial of farudodstat - ASLAN Pharmaceuticals announced that it has dosed the first patient in a Phase 2a proof-of-concept study of farudodstat, an oral dihydroorotate dehydrogenase, DHODH, inhibitor, in adult patients with severe alopecia areata, an autoimmune condition causing hair loss. The study, called "FAST-AA," will investigate farudodstat's efficacy and safety in patients with at least 50% scalp hair loss. "We are excited to begin this trial investigating farudodstat in AA, a disease for which patients have very limited treatment options," said Dr Alex Kaoukhov, Chief Medical Officer of ASLAN Pharmaceuticals. "DHODH is an established target in the treatment of autoimmune diseases, and data from our recent studies support farudodstat's potential to treat AA. The human translational data we presented as a late-breaking abstract at the first International Societies for Investigative Dermatology meeting earlier this month showed that farudodstat not only reduced T cell proliferation but may also protect from immune privilege collapse, potentially offering a novel mechanism for AA treatment." Dr Kaoukhov continued, "FAST-AA will enroll patients in at least 20 sites across the US with a topline readout from the first 12-week treatment period expected in 1Q 2024."

07:14 EDT Tilray's Breckenridge announces limited edition collaboration with Flaviar - Breckenridge Distillery, a subsidiary of Tilray, announced that it has joined forces with Flaviar, America's largest luxury spirits club, to create a limited-edition bourbon called Dad's Stash in celebration of Father's Day.

07:12 EDT Walmart sees FY24 capital expenditures flat to up slightly - Sees FY24 effective tax rate 26.5%.

07:11 EDT PepGen receives NOL for its CTA from Health Canada for Phase 2 CONNECT1-EDO51 - PepGen announced that the company has received a No Objection Letter, NOL, for its Clinical Trial Application, CTA, from Health Canada for its Phase 2 CONNECT1-EDO51 study to initiate an open label, multiple ascending dose, MAD, clinical trial of PGN-EDO51 in patients with Duchenne muscular dystrophy, DMD, amenable to an exon 51 skipping approach. The Company expects to begin dosing patients with PGN-EDO51 in 2H 2023. "Today is the next step in our development of PGN-EDO51, a potentially transformative treatment candidate for people living with DMD. Building upon the encouraging safety, tolerability, and exon skipping data from our Phase 1 healthy volunteer study reported last year showing promising tolerability and exon-skipping activity, we are pleased to continue our work with the DMD community to develop a therapy that we hope will produce meaningful levels of a functional, skipped dystrophin protein," said James McArthur, Ph.D., President and CEO of PepGen. "In addition to our most advanced program, PGN-EDO51, we eagerly anticipate providing the community with updates on our progress to develop transformational therapies for myotonic dystrophy type one (DM1), and other exon skippable mutations for people living with DMD, including 53, 45 and 44. We are leveraging the power of our EDO technology to work to change the future for people living with these devastating diseases."

07:09 EDT Alimera Sciences acquires U.S. commercial rights to YUTIQ from EyePoint - Alimera Sciences (ALIM) announced its acquisition of additional commercialization rights for YUTIQ 0.18mg for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye from EyePoint Pharmaceuticals (EYPT). YUTIQ net product revenue increased 60% to $7.4 million in Q1 2023 compared with $4.6 million in Q1 2022. For the full year of 2022, YUTIQ net product revenue increased 67% to $28.3 million compared to $16.9 million in 2021. Alimera now has exclusive global rights to YUTIQ excluding China, Hong Kong, Taiwan, Macau, South Korea and Southeast Asia, where EyePoint has a pre-existing license with Ocumension Therapeutics. Under the terms of the agreement with EyePoint: Alimera made an upfront cash payment of $75 million at closing; an additional $7.5 million will be paid in equal quarterly installments in 2024. EyePoint will also receive potential royalties from 2025 to 2028 based on combined net revenues in the U.S. from ILUVIEN and YUTIQ in excess of certain thresholds, beginning at $70 million in 2025 and increasing annually thereafter. Alimera will immediately assume control of all commercial activities related to YUTIQ in the U.S. Alimera funded the upfront payment and obtained additional working capital with: A $69 million private placement of Series B preferred stock and common stock to a syndicate of investors led by Velan Capital and Caligan Partners. Borrowing of an additional $20 million through an amendment to its existing term loan agreement with SLR Capital Partners, LLC. In conjunction with these transactions, Alimera has added Jason Werner to its Board of Directors, as a designee of Velan Capital. Prior to this appointment, long-term board member, Garheng Kong, resigned as director. Werner currently serves as the Chief Executive Officer of SightStream Biotherapeutics.

07:06 EDT Bombardier announces May 23 as start of normal course issuer bid - Bombardier confirmed that its previously announced new normal course issuer bid will commence on May 23, 2023, following the early termination of its current normal course issuer bid. The Toronto Stock Exchange has approved Bombardier to purchase, from May 23, 2023 to May 22, 2024, up to 600,000 of its Class B shares under the NCIB, representing approximately 0.72% of the 82,986,942 Class B shares issued and outstanding as of May 10, 2023. The Corporation's current normal course issuer bid commenced on June 28, 2022 for a 12-month period that would have ended June 27, 2023 for a maximum of 880,000 Class B shares. The maximum amount of shares under the 2022 NCIB have been purchased. As permitted by the TSX, the 2022 NCIB will terminate early on May 22, 2023, the day prior to the effective date of the new NCIB. Under the rules of the TSX, the Corporation may generally purchase a maximum of 5% of its issued and outstanding Class B shares over a 12-month period pursuant to a normal course issuer bid. As a result of the 2022 NCIB's early termination, the Corporation must include the number of Class B shares purchased under the 2022 NCIB within the 5% Annual Limit for the new NCIB. As the Corporation intends to purchase up to 600,000 Class B shares pursuant to the new NCIB, these shares, together with the 880,000 Class B shares purchased under the 2022 NCIB, represent approximately 1.78% of the 82,986,942 Class B shares issued and outstanding as of May 10, 2023. All Class B shares purchased under the NCIB will either be cancelled or delivered to a trustee to satisfy future obligations under the Corporation's employee share-based incentive plans. Class B shares purchased under the NCIB will be cancelled if purchased in order to mitigate the dilutive effect of granting stock options under the Corporation's stock option plan, which are settled with Class B shares. Otherwise Class B shares purchased under the NCIB will be placed in trust with Computershare Trust Company of Canada pursuant to the Amended and Restated Employee Benefit Plans Trust Agreement entered into on August 6, 2015 between the Corporation and Computershare Canada, as amended, which Class B shares held in trust will eventually be used to settle the Corporation's obligations under certain of its employee share-based incentive plans, including its performance share unit plan and its restricted share unit plan. Of the up to 600,000 Class B shares that may be purchased under the NCIB, the Corporation currently anticipates that approximately 85,800 of such shares would be cancelled and the balance of such shares would be placed in trust with Computershare Canada.

07:03 EDT AerCap delivers four new Airbus A321neo aircraft to Air India - AerCap Holdings (AER) announced it has completed a mandate for the lease of four new Airbus (EADSY) A321neo aircraft with Air India, the flag carrier of India, following the delivery of the fourth aircraft. The aircraft, powered by CFM LEAP-1A engines, are the first A321neo aircraft to be inducted into the Air India fleet.

06:51 EDT Eli Lilly announces detailed results from peresolimab study published in NEJM - The New England Journal of Medicine, or NEJM, published detailed results from Eli Lilly's phase 2a study of peresolimab in rheumatoid arthritis, or RA, in which peresolimab met the primary endpoint for efficacy and had similar rates of adverse events between peresolimab and placebo arms. These data represent the first clinical evidence that stimulating the endogenous PD-1 inhibitory pathway could be an effective approach to treat rheumatologic disease. The phase 2a clinical trial evaluated the safety and efficacy of peresolimab in adult participants with moderate-to-severe RA who had an inadequate response to prior conventional, biologic or synthetic disease modifying antirheumatic drugs, or DMARDs.

06:13 EDT Brunswick's Mercury Marine announces partnership with JJE - Mercury Marine, a division of Brunswick, has entered into an agreement with JJE, an electrified propulsion leader in components, assemblies, and systems for global automotive applications. This partnership will enhance Mercury's stated goal of leading the marine industry in both internal combustion propulsion and electrification and will broaden JJE's goal to be a diversified electric powertrain supplier across several verticals. The collaboration will enable Mercury to expand its portfolio of electric propulsion solutions - advancing to higher power electric systems.

06:11 EDT Air Products extends term of CEO, chairman Seifi Ghasemi - Air Products' board of directors announced an amendment to the employment agreement with Air Products' chairman, president and chief executive officer, Seifi Ghasemi, further extending his term. The company has entered into a new amended agreement that will initially extend Ghasemi's employment term to September 30, 2028. On September 30, 2024 and each year thereafter, the contract term will automatically renew to be a five-year term unless either party terminates the agreement at the latest, four years ahead of its then expiration date.

06:07 EDT Adicet Bio's ADI-270 shows anti-tumor activity in preclinical study - Adicet Bio announced preclinical data highlighting ADI-270, an armored allogeneic "off-the-shelf" gamma delta CAR - chimeric antigen receptor - T cell therapy candidate targeting CD70+ cancers, at the 26th Annual Meeting of the American Society of Gene & Cell Therapy from May 16-20, in Los Angeles. In this study, gamma delta T cells modified to express CD70 CAR were successfully generated and expanded without evident hindrances from CD70-mediated fratricide in the process. ADI-270 demonstrated preclinical proof-of-concept as an armored allogeneic gamma delta CAR T cell therapy candidate utilizing the CD27 natural receptor in a third generation CAR format for targeting CD70-positive cancers. ADI-270 gamma delta 1 CAR T cells expressed a predominant naive-like memory phenotype with potent in vitro cytotoxicity and production of proinflammatory cytokines against CD70+ tumor cell lines via multiple mechanisms. ADI-270 showed significant inhibition of tumor growth in CD70+ tumor cell lines, which was maintained in the presence of TGF beta inhibitory factor, and exhibited improved resistance to killing by host T cell rejection. ADI-270 also demonstrated marked biodistribution and infiltration into solid tumor models of renal cell carcinoma.

06:05 EDT Dole still sees 2023 adjusted EBITDA $350M

05:31 EDT Apple expands Apple Store online into Vietnam - Apple announced the expansion of the Apple Store online into Vietnam. Customers throughout the country can now shop direct with Apple and receive service, delivered by team members who are ready to share their expertise in Vietnamese.

05:13 EDT Addex Therapeutics receives noncompliance notification from Nasdaq - Addex Therapeutics announced that it had received written notification from Nasdaq indicating that, for the last thirty consecutive business days, the bid price for the company's American Depositary Shares, or ADSs, had closed below the minimum $1.00 per ADS requirement for continued listing on Nasdaq under listing rule 5550.